La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?

échéance 2026-12-22 confiance moyenne preuve niveau 4

63 %estimation Asturna

Critère de résolution

Se résout par OUI si la FDA publie une approbation (Drugs@FDA ou communiqué officiel Mineralys Therapeutics) du lorundrostat contre l'hypertension chez l'adulte au plus tard le 22 décembre 2026. Une lettre de réponse complète, un report de la date PDUFA ou l'absence de décision valent NON. Ceci se résout sur une approbation spécifiquement pour l'hypertension (toute sévérité, y compris l'hypertension résistante) ; une approbation pour une indication non liée (par ex. apnée du sommeil seule) ne compte pas comme oui.

État de départ vérifié

Dossier accepté, date PDUFA au 22 décembre 2026. Inhibiteur de l'aldostérone synthase, une classe mécanistique pas encore approuvée aux États-Unis contre l'hypertension. Un essai de phase 2 lié, sur l'apnée obstructive du sommeil (Explore-OSA), a rapporté des résultats en deçà des attentes le même jour que l'acceptation du dossier — sans rapport avec l'indication hypertension examinée ici. (communiqué Mineralys Therapeutics / dépôt SEC, 6 mars 2026)

Les arguments ci-dessous ont été produits par le modèle en anglais. Ils sont affichés tels quels plutôt que traduits automatiquement, pour que rien sur cette page ne soit un texte que Asturna n'a pas réellement écrit.

Ce qui fait monter

The FDA accepted the NDA for lorundrostat in hypertension with a PDUFA action date set for December 22, 2026 [tier 1].

Ce qui fait descendre

Lorundrostat belongs to a novel class (aldosterone synthase inhibitors) not yet approved in the US for hypertension, presenting safety and efficacy scrutiny around hyperkalemia and off-target steroidogenesis suppression [tier 1].
Topline results from a Phase 2 trial (Explore-OSA) in a secondary indication fell short, highlighting potential trial variability or safety nuances [tier 1].

Ce qui ferait le plus bouger ce chiffre

Whether the FDA identifies safety issues (such as hyperkalemia or adrenal insufficiency) or requests additional clinical/manufacturing data during the final review phase before the December 22, 2026 PDUFA date.

Comment ce chiffre est fabriqué

Échéance	2026-12-22
Taux de base	64%
Meilleure preuve	niveau 4 · 0 article(s) utilisé(s)
Estimations	62 · 63 (écart 1 pts)
Confiance	moyenne
Plafond de preuve	non déclenché
Révisée le	2026-10-18 09:09
Modèle	gemini-3.6-flash

Historique de la probabilité

2026-10-18 09:09 63% 103 article(s) au dossier · gemini-3.6-flash

Ce qui fait monter. The FDA accepted the NDA for lorundrostat in hypertension with a PDUFA action date set for December 22, 2026 [tier 1].
Ce qui fait descendre. Lorundrostat belongs to a novel class (aldosterone synthase inhibitors) not yet approved in the US for hypertension, presenting safety and efficacy scrutiny around hyperkalemia and off-target steroidogenesis suppression [tier 1].
Ce qui fait descendre. Topline results from a Phase 2 trial (Explore-OSA) in a secondary indication fell short, highlighting potential trial variability or safety nuances [tier 1].
Ce qui ferait le plus bouger ce chiffre. Whether the FDA identifies safety issues (such as hyperkalemia or adrenal insufficiency) or requests additional clinical/manufacturing data during the final review phase before the December 22, 2026 PDUFA date.

2026-10-17 09:07 57% 97 article(s) au dossier · gemini-3.8-flash

Ce qui fait monter. Lorundrostat's NDA for hypertension is actively under FDA review with an established PDUFA target action date of 22 December 2026, with no CRL or review extension reported to date [tier 1].
Ce qui fait descendre. The resolution criteria specify that any postponement of the PDUFA date counts as a NO, and standard three-month major amendment extensions occur in roughly 10-15% of novel mechanism reviews [tier 2].
Ce qui fait descendre. Lorundrostat represents a first-in-class aldosterone synthase inhibitor, a novel mechanism class not previously approved in the US for hypertension, carrying elevated regulatory and safety scrutiny [tier 1].
Ce qui ferait le plus bouger ce chiffre. Whether the FDA issues a standard three-month PDUFA extension for chemistry, manufacturing, and controls (CMC) or labeling amendments before 22 December 2026.

2026-10-14 12:06 60% 83 article(s) au dossier · gemini-3-flash-preview

Ce qui fait monter. The FDA has accepted the NDA for lorundrostat with a PDUFA target action date of December 22, 2026, which aligns with the resolution deadline [tier 1].
Ce qui fait monter. Aldosterone synthase inhibition is a scientifically validated target for hypertension, even if this is the first of its class seeking US approval [tier 1].
Ce qui fait descendre. A related Phase 2 trial (Explore-OSA) for obstructive sleep apnea failed to meet its topline results, which may indicate limitations in the drug's broader clinical profile [tier 1].
Ce qui fait descendre. As a first-in-class mechanism, lorundrostat faces higher regulatory scrutiny and a higher risk of a Complete Response Letter or review extension [tier 1, tier 2].
Ce qui fait descendre. Manufacturing site issues or the need for additional data can lead to PDUFA extensions, which would result in a NO resolution under these criteria [tier 2].
Ce qui ferait le plus bouger ce chiffre. The primary uncertainty is whether the FDA will require an Advisory Committee meeting or identify safety/manufacturing concerns during the final two months of the review cycle.

2026-10-13 12:09 59% 83 article(s) au dossier · gemini-3-flash-preview

Ce qui fait monter. The FDA has accepted the NDA for lorundrostat with a specific PDUFA target action date of December 22, 2026 [1].
Ce qui fait descendre. Lorundrostat uses a novel mechanism (aldosterone synthase inhibitor) not yet approved in the US for hypertension, which typically attracts higher regulatory scrutiny [1].
Ce qui fait descendre. A related Phase 2 trial (Explore-OSA) for obstructive sleep apnea failed to meet its topline results, which may raise questions about the drug's broader efficacy or safety profile [1].
Ce qui fait descendre. The PDUFA date is exactly on the resolution deadline; any review extension, which is common for novel mechanisms or manufacturing issues, would result in a 'No' resolution [1, 18].
Ce qui ferait le plus bouger ce chiffre. The primary uncertainty is whether the FDA will identify any clinical or manufacturing issues requiring a Complete Response Letter or a review extension, especially given the novel mechanism and the failure of the related OSA trial.

2026-10-12 12:01 57% 74 article(s) au dossier · gemini-flash-latest

Ce qui fait monter. Lorundrostat's NDA has been accepted for review with an assigned PDUFA target action date of 22 December 2026, and review remains on track [tier 1].
Ce qui fait descendre. The resolution criteria specify that any postponement of the PDUFA date counts as 'no'; first-cycle approval statistics include reviews extended by 3-month major amendments, making the on-time probability strictly lower than the 64% base rate [tier 1].
Ce qui fait descendre. As a first-in-class aldosterone synthase inhibitor for hypertension, regulatory scrutiny on selectivity and safety (e.g., hyperkalemia and adrenocortical effects) presents elevated risk of CRL or requests for additional analyses [tier 1].
Ce qui fait descendre. Mineralys Therapeutics is an emerging biotech managing its initial NDA filing, which historically carries slightly higher rates of review delay or manufacturing/data queries than large pharmaceutical sponsors [tier 1].
Ce qui ferait le plus bouger ce chiffre. Whether the FDA issues a decision on or before the exact PDUFA date of 22 December 2026 or triggers a standard 3-month clock extension for major amendments.

2026-10-11 09:15 59% 74 article(s) au dossier · gemini-3.7-flash

Ce qui fait monter. Lorundrostat's NDA for hypertension was accepted with an established PDUFA target action date of 22 December 2026 [tier 1].
Ce qui fait monter. No negative regulatory developments, complete response letters, or safety warnings have been reported regarding the hypertension program as of October 2026 [tier 1].
Ce qui fait descendre. Lorundrostat is an aldosterone synthase inhibitor, a novel mechanism class not previously approved in the US for hypertension, carrying elevated safety and regulatory scrutiny [tier 1].
Ce qui fait descendre. The resolution criteria strictly require approval on or before 22 December 2026, meaning any standard three-month PDUFA review extension pushes the decision into 2027 and resolves as No [tier 1].
Ce qui ferait le plus bouger ce chiffre. Whether the FDA requests additional clinical or chemistry, manufacturing, and controls (CMC) data that triggers a three-month PDUFA extension or a Complete Response Letter.

2026-10-08 09:11 66% 57 article(s) au dossier · gemini-3-flash-preview

Ce qui fait monter. The FDA accepted the NDA for lorundrostat with a PDUFA target action date of December 22, 2026, which aligns with the resolution deadline [1].
Ce qui fait monter. Mineralys Therapeutics has been actively raising funds and preparing for a commercial launch, signaling corporate confidence in the upcoming regulatory decision [2].
Ce qui fait monter. There have been no reports of FDA-mandated delays, advisory committee meetings, or major safety concerns since the NDA was accepted in March 2026 [1, 2].
Ce qui fait descendre. The PDUFA date is the final day of the resolution window; any 3-month extension or minor administrative delay would result in a 'No' resolution [1].
Ce qui fait descendre. Lorundrostat is an aldosterone synthase inhibitor, a mechanism class not yet approved in the US for hypertension, which may invite higher regulatory scrutiny [1].
Ce qui fait descendre. A related Phase 2 trial for obstructive sleep apnea failed to meet its topline results, which could potentially raise questions about the drug's broader efficacy profile [1].
Ce qui ferait le plus bouger ce chiffre. The primary uncertainty is whether the FDA will require a standard 3-month extension to review the new mechanism of action, which would push the decision past the December 22 deadline.

2026-10-02 09:10 67% 31 article(s) au dossier · openai/gpt-oss-120b (Groq)

Ce qui fait monter. Company’s public moves suggest confidence in an imminent hypertension approval (Endpoints News, tier 2)
Ce qui fait monter. NDA acceptance and a set PDUFA target date indicate FDA is proceeding toward a decision (hand‑verified tier 1)
Ce qui fait descendre. Recent Phase 2 OSA trial failed, raising possible safety/efficacy concerns for the same molecule (hand‑verified tier 1)
Ce qui fait descendre. Base‑rate for new‑mechanism drugs is only 64%, reflecting inherent uncertainty
Ce qui ferait le plus bouger ce chiffre. The FDA’s final decision at the PDUFA date – whether it issues approval or a complete response letter.

2026-10-01 09:01 65% 26 article(s) au dossier · openai/gpt-oss-20b (Groq)

Ce qui fait monter. NDA acceptance and scheduled PDUFA date indicate a review will occur, raising the likelihood of approval. [1]
Ce qui fait descendre. No tier 1 or 2 evidence of approval or positive data for hypertension, and the mechanism is new with no prior approvals, lowering confidence. [4]
Ce qui ferait le plus bouger ce chiffre. Whether the FDA will find the efficacy and safety data sufficient for approval; a rejection would drop the probability dramatically.

2026-09-30 17:00 60% 17 article(s) au dossier · openai/gpt-oss-20b (Groq)

Ce qui fait monter. NDA acceptance and a PDUFA target date of 22 Dec 2026 indicate the FDA has moved the application forward (tier 2).
Ce qui fait descendre. No hypertension efficacy data or safety signals have been reported; the mechanism is novel and has no prior approvals, lowering confidence in a favorable outcome (tier 2).
Ce qui ferait le plus bouger ce chiffre. The availability and quality of hypertension trial data and the safety profile of lorundrostat will most influence the approval likelihood.